Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.66
(3.29%)
INR 16.66
(3.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.04 Billion INR | 7.1% |
| 2022 | 3.77 Billion INR | 22.58% |
| 2021 | 3.08 Billion INR | 5.69% |
| 2020 | 2.91 Billion INR | 61.56% |
| 2019 | 1.8 Billion INR | 4.37% |
| 2018 | 1.72 Billion INR | 1.17% |
| 2017 | 1.7 Billion INR | -2.35% |
| 2016 | 1.75 Billion INR | 2.71% |
| 2015 | 1.7 Billion INR | 23.88% |
| 2014 | 1.37 Billion INR | -1.73% |
| 2013 | 1.4 Billion INR | 13.97% |
| 2012 | 1.22 Billion INR | 8.99% |
| 2011 | 1.12 Billion INR | -0.26% |
| 2010 | 1.13 Billion INR | 22.44% |
| 2009 | 923.18 Million INR | 45.83% |
| 2008 | 633.06 Million INR | -6.88% |
| 2007 | 679.82 Million INR | 26.04% |
| 2006 | 539.37 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 4.04 Billion INR | 0.0% |
| 2023 Q2 | 4.03 Billion INR | 0.0% |
| 2023 FY | 4.04 Billion INR | 7.1% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.76 Billion INR | 0.0% |
| 2022 FY | 3.77 Billion INR | 22.58% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 3.77 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 3.08 Billion INR | 5.69% |
| 2021 Q4 | 3.08 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 3.04 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q4 | 2.91 Billion INR | 0.0% |
| 2020 FY | 2.91 Billion INR | 61.56% |
| 2020 Q2 | 2.21 Billion INR | 0.0% |
| 2019 Q4 | 1.8 Billion INR | 0.0% |
| 2019 Q2 | 1.81 Billion INR | 0.0% |
| 2019 FY | 1.8 Billion INR | 4.37% |
| 2018 Q4 | 1.72 Billion INR | 0.0% |
| 2018 FY | 1.72 Billion INR | 1.17% |
| 2018 Q2 | 1.62 Billion INR | 0.0% |
| 2017 Q4 | 1.7 Billion INR | 0.0% |
| 2017 FY | 1.7 Billion INR | -2.35% |
| 2016 FY | 1.75 Billion INR | 2.71% |
| 2016 Q4 | 1.75 Billion INR | 0.0% |
| 2015 Q2 | 1.34 Billion INR | 0.0% |
| 2015 Q4 | 1.7 Billion INR | 0.0% |
| 2015 FY | 1.7 Billion INR | 23.88% |
| 2014 Q2 | 1.37 Billion INR | 0.0% |
| 2014 Q4 | 1.37 Billion INR | 0.0% |
| 2014 FY | 1.37 Billion INR | -1.73% |
| 2013 Q2 | 1.21 Billion INR | 0.0% |
| 2013 Q4 | 1.4 Billion INR | 0.0% |
| 2013 FY | 1.4 Billion INR | 13.97% |
| 2012 FY | 1.22 Billion INR | 8.99% |
| 2012 Q4 | 1.22 Billion INR | 0.0% |
| 2012 Q2 | 2.25 Billion INR | 0.0% |
| 2011 FY | 1.12 Billion INR | -0.26% |
| 2010 FY | 1.13 Billion INR | 22.44% |
| 2009 FY | 923.18 Million INR | 45.83% |
| 2008 FY | 633.06 Million INR | -6.88% |
| 2007 FY | 679.82 Million INR | 26.04% |
| 2006 FY | 539.37 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 93.722% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.102% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 85.803% |
| Granules India Limited | 55.2 Billion INR | 92.67% |
| Indoco Remedies Limited | 21.44 Billion INR | 81.132% |
| Achyut Healthcare Limited | 309.52 Million INR | -1207.383% |
| Ajanta Pharma Limited | 46.38 Billion INR | 91.276% |
| Alkem Laboratories Limited | 155.74 Billion INR | 97.402% |
| Alpa Laboratories Limited | 1.82 Billion INR | -121.586% |
| Brooks Laboratories Limited | 904.45 Million INR | -347.412% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 62.463% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 47.112% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 66.663% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.956% |
| Eris Lifesciences Limited | 70.48 Billion INR | 94.259% |
| FDC Limited | 24.68 Billion INR | 83.604% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 97.182% |
| Gufic Biosciences Limited | 10.92 Billion INR | 62.961% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 65.268% |
| Ipca Laboratories Limited | 111.01 Billion INR | 96.355% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -86.414% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -127.116% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -168.223% |
| Laurus Labs Limited | 83.87 Billion INR | 95.175% |
| Lupin Limited | 239.97 Billion INR | 98.314% |
| Mankind Pharma Limited | 119.63 Billion INR | 96.617% |
| Medicamen Biotech Limited | 2.94 Billion INR | -37.397% |
| Medico Remedies Limited | 961.95 Million INR | -320.669% |
| Megasoft Limited | 3.65 Billion INR | -10.594% |
| NATCO Pharma Limited | 69.06 Billion INR | 94.141% |
| Piramal Pharma Limited | 153.11 Billion INR | 97.357% |
| RPG Life Sciences Limited | 5.12 Billion INR | 21.098% |
| Sigachi Industries Limited | 6.94 Billion INR | 41.704% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.527% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 82.048% |
| Unichem Laboratories Limited | 31.69 Billion INR | 87.232% |
| Wanbury Limited | 3.43 Billion INR | -17.808% |
| Windlas Biotech Limited | 6.26 Billion INR | 35.378% |
| ZIM Laboratories Limited | 4.46 Billion INR | 9.435% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.618% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 21.431% |
| Divi's Laboratories Limited | 154.7 Billion INR | 97.384% |
| Hester Biosciences Limited | 6.62 Billion INR | 38.905% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 49.058% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -10.302% |
| Bal Pharma Limited | 3.2 Billion INR | -26.304% |
| Strides Pharma Science Limited | 58.39 Billion INR | 93.071% |
| Venus Remedies Limited | 6.26 Billion INR | 35.443% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 84.328% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 81.531% |
| Shilpa Medicare Limited | 30.93 Billion INR | 86.918% |
| Aarti Drugs Limited | 24.32 Billion INR | 83.363% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 81.97% |
| Suven Life Sciences Limited | 2.84 Billion INR | -42.036% |
| Ind-Swift Limited | 6.54 Billion INR | 38.169% |
| Valiant Laboratories Limited | 3.42 Billion INR | -18.085% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 89.869% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 82.787% |
| Themis Medicare Limited | 5.66 Billion INR | 28.557% |
| Hikal Limited | 24.87 Billion INR | 83.73% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 97.313% |
| Sequent Scientific Limited | 15.4 Billion INR | 73.73% |
| Novartis India Limited | 9.24 Billion INR | 56.249% |
| Wockhardt Limited | 76.49 Billion INR | 94.71% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 96.496% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -759.475% |
| Neuland Laboratories Limited | 18.32 Billion INR | 77.918% |
| Morepen Laboratories Limited | 12.93 Billion INR | 68.708% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -68.567% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -21.366% |